A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Serum Integrated Screen, Part 2
Test Code16167
CPT Codes
81511<br><strong>This test code is for non-New York patient testing. For New York patient testing, use test code 16966. </strong><br><strong>This test is not available for California patient testing.</strong>
Includes
AFP, Unconjugated Estriol, hCG, Dimeric Inhibin A, PAPP-A (Pregnancy-associated Plasma Protein-A) from Maternal Serum, Serum Integrated Screen, Part 1 and Interpretation
Preferred Specimen
3 mL serum
Minimum Volume
1 mL
Instructions
Collect between 14.0 weeks to 22.9 weeks.
Maternal date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results.
Must complete patient demographic information using the Maternal Serum Screen Requisition.
Maternal date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results.
Must complete patient demographic information using the Maternal Serum Screen Requisition.
Transport Container
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic
Methodology
Chemiluminescence (CL) • Immunoassay (IA)
FDA Status
PAPP-A: This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics. This test should not be used for diagnosis without confirmation by other medically established means.
Setup Schedule
Set up: Mon-Sat; Report available: 4-6 days
Limitations
Serum Integrated Screen results consistent with an increased risk of trisomy should be confirmed with amniotic fluid specimen. Results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.
Reference Range
See Laboratory Report
Clinical Significance
To assess maternal risk for carrying a fetus with Down Syndrome (Trisomy 21), Trisomy 18, or a neural tube defect. These types of tests are standard-of-care in obstetrics.
Performing Laboratory
Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
33608 Ortega Highway |
San Juan Capistrano, CA 92675-2042 |